Purpose of review: To summarize recent advances with respect to the use of genome editing to modify blood lipid levels in vivo.
Recent findings: Genome-editing technologies have been successfully used to target the PCSK9 gene in the livers of nonhuman primates and significantly reduce blood LDL cholesterol levels.
Summary: Multiple proof-of-concept nonhuman primate studies raise the prospect of genome editing empowering 'one-and-done' therapies for the treatment of dyslipidemic patients.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.